PhaseRx, a preclinical biotech developing treatments for inherited enzyme deficiencies in the liver, filed on Monday with the SEC to raise up to $30 million in an initial public offering.
The Seattle, WA-based company was founded in 2006 and booked $0 million in sales for the 12 months ended December 31, 2015. It plans to list on the Nasdaq under the symbol PZRX. Laidlaw & Company (UK) is the sole bookrunner on the deal. No pricing terms were disclosed.
